ArticleCureus2026
Vaccination Challenges and Outcomes in Patients Undergoing Hemodialysis: Experience From a Pharmacist-Led Program in Singapore.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Patients receiving maintenance hemodialysis experience a high burden of infectious morbidity, and vaccination is a key preventive strategy in this population. Despite international guideline recommendations, vaccination uptake and immune response in this population remain suboptimal. Aims The study aimed to evaluate hepatitis B virus (HBV) vaccination completion and seroprotection, pneumococcal vaccination coverage, and pneumonia-related hospitalizations among incident hemodialysis patients managed under a pharmacist-led vaccination program. Design This retrospective cohort study was conducted between 2019 and 2022 at a tertiary hospital dialysis program in Singapore, where vaccination delivery was integrated into routine hemodialysis care by clinical pharmacists. Methods All consecutive incident adult hemodialysis patients managed between January 2019 and December 2022 under a pharmacist-led vaccination model were included. They were evaluated for vaccination uptake, immune response to HBV vaccination, and pneumonia-related hospitalizations within the first year of dialysis initiation. Data were extracted from the hospital's electronic medical record (EMR) system. As this was a service evaluation of the entire eligible population during the study period, no formal sample size calculation was performed. Statistical analysis Categorical variables were analyzed using chi-square testing, with statistical significance defined as a two-sided p-value < 0.05. Results are reported with corresponding chi-square statistics and p-values where applicable. Results Among HBV-susceptible patients, just over one-third completed the recommended three-dose vaccination schedule, and approximately half of those achieved seroprotection. Pneumococcal vaccination coverage within the first year of hemodialysis initiation was below 50%. Pneumonia-related hospitalizations were lower among vaccinated patients (2.2%) compared with unvaccinated patients (7.5%) and were statistically significant (p = 0.032). Conclusions A pharmacist-led vaccination program was associated with moderate vaccine uptake and reduced pneumonia-related hospitalizations; however, substantial gaps in vaccination completion and immune response persisted. Multicomponent, system-level strategies may be required to enhance vaccine uptake and effectiveness in hemodialysis populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.